Steno2tech - Continuous Glucose Monitoring and Type 2 Diabetes.

Type 2 Diabetes Treated With Insulin Clinical Trial

Official title:

Steno2tech CGM-The Effect of Real-time Continuous Glucose Monitoring vs. Self-monitoring of Blood Glucose on Glycemic Variables and Patient Reported Outcomes in Adults With Type 2 Diabetes Treated With Insulin-A Randomized Controlled Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04331444
• Other study ID #: Steno2tech CGM
• Status: Completed
• Phase: N/A
• Start date: August 1, 2020
• Est. completion date: July 1, 2023

Study information

• Verified date: October 2023
• Source: Steno Diabetes Center Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall objective of this research study is to examine the effectiveness of the use of CGM vs. SMBG in persons with insulin-treated type 2 diabetes on glycemic variables and patient reported outcomes on treatment satisfaction, health behavior and wellbeing. The independent effect of peer-support will also be studied.

Description:

The prevalence of type 2 diabetes is increasing. Although medical treatment options have increased, still less than a third obtain their optimal glycemic goal. The use of continuous glucose monitoring (CGM) in persons with type 1 diabetes has shown to be the most important driver for improvement in glycemic control-even more than insulin-pump therapy-but the use of technology in type 2 diabetes are not yet reimbursed and has been investigated in very few studies.

The study will be a single center, prospective, randomized, open-labelled, three-armed study with the randomization 2:1:2 in group A with CGM, group B with CGM and peer-support, group C as a control group with SMBG. The study will run for 12 months and will include 100 adult participants with insulin-treated type 2 diabetes, treated at the outpatient clinic at Steno Diabetes Center Copenhagen. Recruitment will begin in August 2020 and end in May 2022. Final 12-month follow-up is anticipated to be in July 2023.

The study is investor-initiated. The primary investigator (Nanna Lind, PhD. Student) will be responsible for execution of this study under guidance by the sponsor Kirsten Nørgaard. Results will be published in international peer-reviewed journals.

Our study will provide evidence of the effectiveness of the use of CGM in the treatment for type 2 diabetes, potentially shaping clinical guidelines for SMBG frequency and timing as well as use of technology in type 2 diabetes with an impact on both healthcare and healthcare costs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: July 1, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Type 2 diabetes according to clinical definitions

• Treated with insulin injections at least once daily on top of diet and exercise recommendations. Insulin therapy has been used for at least 12 months. Can be additionally treated with one or more different oral antidiabetic drugs (except sulfonylurea), and/or glucagon-like-peptide 1 (GLP-1) analogues

• Attending the outpatient clinic at Steno Diabetes Center Copenhagen for at least 12 months

• Age = 18 years

• HbA1c > 58 mmol/mol (7.5%) at two consecutively measurements over at least 3 months

• Willing to use possible interventions; to perform self-monitoring of blood glucose (SMBG) as requested by the investigators AND to use CGM continuously without calibration for a 12-month period.

• Willing to intensify non-medical and medical treatment to achieve better glucose control.

Exclusion Criteria:

• Inability to understand the patient information and give informed consent

• Not speaking and understanding Danish

• Treatment with sulfonylurea (SU) during the last 3 months before study start

• New antidiabetic treatment the last three months

• Use of systematic corticosteroids

• Visual impairment

• Severe skin allergy for adhesive tape to the patch of CGM or other skin condition that inhibits the use of a CGM device

• Comorbidity which does not allow lowering of HbA1c to 53 mmol/mol (7.0%)

• Hypoglycemic unawareness

• Impaired renal disease with eGFR < 45 ml/min/1.73m2

• Conditions that impact the stability of a HbA1c measurement (chronic liver disease, haemoglobinopathy, anemia etc.)

• Known or suspected alcohol or drug abuse

• Already using Flash glucose monitoring (Libre) or CGM

• Enrolled in another clinical study

• Pregnancy, intend to become pregnant, breastfeeding or not using adequate contraceptive methods

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Treated With Insulin

Intervention

Device:
• CGM
Using the CGM during the entire study period of 12 months.

Behavioral:
• training course
The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.
• Peer-support
The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.

Locations

Country	Name	City	State
Denmark	Steno Diabetes Center Copenhagen	Gentofte	Hovedstaden

Sponsors (1)

Lead Sponsor	Collaborator
Steno Diabetes Center Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluating which blood glucose measured by SMBG best reflect TIR	(fasting, pre-prandial or postprandial)	from baseline to 12 months
Primary	Difference between change in TIR (3.9-10 mmol/l) in percent, assessed via blinded CGM device, between CGM group (A) and SMBG group (C)	Percent	from baseline to 12 months
Secondary	Difference between change in HbA1c between the CGM group (A) and the SMBG group (C)	mmol/mol	from baseline to 12 months
Secondary	Difference between change in mean sensor glucose concentration measured by 2 weeks blinded CGM between the CGM group (A) and the SMBG group (C)	mmol/l	from baseline to 12 months
Secondary	Difference between change in time below range (TBR) (< 3.9 mmol/l, < 3.0 mmol/l), in percent, measured by 2 weeks blinded CGM between the CGM group (A) and the SMBG group (C)	Percent	from baseline to 12 months
Secondary	Difference between change in time above range (TAR) (>10 mmol/l, > 13.9 mmol/l), in percent, measured by 2 weeks blinded CGM, between the CGM group (A) and the SMBG group (C)	Percent	from baseline to 12 months
Secondary	Difference between change in glycemic variability (SD, Coefficient of variance and others), measured by 2 weeks blinded CGM between the CGM group (A) and the SMBG group (C)	Percent	from baseline to 12 months
Secondary	Difference between change in number of severe hypoglycemic episodes between the CGM group (A) and the SMBG group (C)	number	from baseline to 12 months
Secondary	Difference between change in insulin dose between the CGM group (A) and the SMBG group (C)	units	from baseline to 12 months
Secondary	Difference between change in BMI between the CGM group (A) and the SMBG group (C)	weight and height will be combined to report BMI in kg/m^2	from baseline to 12 months
Secondary	Difference between change in antidiabetic medicine between the CGM group (A) and the SMBG group (C)	(new medication, change in doses, discontinuation of medicine)	from baseline to 12 months
Secondary	Difference between change in patients related outcome measures on general wellbeing, between the CGM group (A) and the SMBG group (C)	measured by the questionnaire WHO-5	from baseline to 12 months
Secondary	Difference between change in patients related outcome measures on diabetes-related distress, between the CGM group (A) and the SMBG group (C)	measured by the Diabetes Distress Scale	from baseline to 12 months
Secondary	Difference between change in patients related outcome measures on hypoglycemia fear between the CGM group (A) and the SMBG group (C)	measured by the short form Hypoglycemia Fear Survey	from baseline to 12 months
Secondary	Difference between change in patients related outcome measures on diabetes treatment satisfaction between the CGM group (A) and the SMBG group (C)	measured by the Diabetes Treatment Satisfaction Quenstionnaire	from baseline to 12 months
Secondary	Difference between change in patients related outcome measures on satisfaction with glucose monitor between the CGM group (A) and the SMBG group (C)	measured by the Glucose Monitoring Satisfaction Scale	from baseline to 12 months
Secondary	Difference between change in health behavior regarding exercise between the CGM group (A) and the SMBG group (C)	measured by the Swedish National Board of Health and Welfare questionnaire for Physical Activity	from baseline to 12 months
Secondary	Difference between change in health behavior regarding diet between the CGM group (A) and the SMBG group (C)	measured by the Danish Perceived Dietary Adherence questionnaire	from baseline to 12 months
Secondary	Difference between change in health behavior regarding anti-diabetic medication adherence between the CGM group (A) and the SMBG group (C)	measured by the Danish Medical Adherence Scale	from baseline to 12 months
Secondary	Difference between change in TIR, assessed by 2 weeks blinded CGM device, and HbA1c between the CGM groups (without peer-support group A and with peer-support group B)	Percent	from baseline to 12 months
Secondary	Difference between change in general wellbeing between the CGM groups (without peer-support group A and with peer-support group B)	measured by the questionnaire WHO-5	from baseline to 12 months
Secondary	Difference between change in diabetes-related distress between the CGM groups (without peer-support group A and with peer-support group B)	measured by the Diabetes Distress Scale	from baseline to 12 months
Secondary	Difference between change in hypoglycemia fear between the CGM groups (without peer-support group A and with peer-support group B)	measured by the short form Hypoglycemia Fear Survey	from baseline to 12 months
Secondary	Difference between change in glucose monitoring satisfaction between the CGM groups (without peer-support group A and with peer-support group B)	measured by the Glucose Monitoring Satisfaction Scale	from baseline to 12 months
Secondary	Difference between change in diabetes treatment satisfaction between the CGM groups (without peer-support group A and with peer-support group B)	measured by the Diabetes Treatment Satisfaction Quenstionnaire	from baseline to 12 months
Secondary	Difference between change in health behavior regarding exercise between the CGM groups (without peer-support group A and with peer-support group B)	measured by the Swedish National Board of Health and Welfare questionnaire for Physical Activity	from baseline to 12 months
Secondary	Difference between change in health behavior regarding diet between the CGM groups (without peer-support group A and with peer-support group B)	measured by the Danish Perceived Dietary Adherence questionnaire	from baseline to 12 months
Secondary	Difference between change in health behavior regarding anti-diabetic medication adherence between the CGM groups (without peer-support group A and with peer-support group B)	measured by the Danish Medical Adherence Scale	from baseline to 12 months
Secondary	Difference in mean number of days of CGM use between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	days	from baseline to 12 months
Secondary	Difference in HbA1c baseline between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	mmol/mol	from baseline to 12 months
Secondary	Difference in age between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	in years	from baseline to 12 months
Secondary	Difference in diabetes duration between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	in years	from baseline to 12 months
Secondary	Difference in C-peptide between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	pmol/l	from baseline to 12 months
Secondary	Difference in education level between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	Percent	from baseline to 12 months
Secondary	Difference in social status between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	measured by civil status and occupation	from baseline to 12 months
Secondary	Difference in ethnicity between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	white/non-white	from baseline to 12 months
Secondary	Difference in medicine used between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)		from baseline to 12 months
Secondary	Difference in change in health behavior regarding to diet between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	measured by the Danish Perceived Dietary Adherence questionnaire	from baseline to 12 months
Secondary	Difference in change in health behavior regarding to exercise between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	measured by the Swedish National Board of Health and Welfare questionnaire for Physical Activity	from baseline to 12 months
Secondary	Difference in change in health behavior regarding to medication adherence between individuals achieving TIR> 70% vs TIR< 70% within the CGM groups (group A+B)	measured by the Danish Medical Adherence Scale	from baseline to 12 months
Secondary	Correlation between mean number of SMBG/day and time points for SMBG in the study period and improvement in HbA1c, in TIR, in TBR, in TAR within the control group C		from baseline to 12 months
Secondary	Difference between number of participants using CGM vs. not using CGM increasing 5 % or more in TIR	number	from baseline to 12 months